Zeffy vs Uncommon Therapeutics

Side-by-side comparison of AI visibility scores, market position, and capabilities

Uncommon Therapeutics leads in AI visibility (27 vs 26)

Zeffy

EmergingNonprofit Tech

Zero-Fee Fundraising

Montreal zero-fee nonprofit fundraising platform with $1B+ processed; 100% donation pass-through via optional donor tips competing with Donorbox and Classy for nonprofit fundraising technology adoption.

AI VisibilityBeta
Overall Score
D26
Category Rank
#1 of 1
AI Consensus
68%
Trend
stable
Per Platform
ChatGPT
19
Perplexity
26
Gemini
17

About

Zeffy is a Montreal-based fundraising platform for nonprofit organizations that charges zero platform fees on donations — asking donors to optionally contribute a tip to cover Zeffy's operating costs rather than deducting fees from each donation, ensuring 100% of every donated dollar reaches the nonprofit cause. Founded in 2019 by Thibaut Davoult and Nicolas Lafleur, Zeffy has processed $1+ billion in nonprofit donations and provides a comprehensive suite including online donation forms, event ticketing, peer-to-peer fundraising campaigns, recurring donation management, and membership management — giving nonprofits a full fundraising platform at genuinely zero cost.

Full profile

Uncommon Therapeutics

EmergingHealthcare

General

Rare disease biotech developing polytherapy approach for Rett Syndrome (1 in 10,000 girls); founder-developed protocol validated through personal patient experience competing with Acadia Pharmaceuticals Daybue in Rett market.

AI VisibilityBeta
Overall Score
D27
Category Rank
#1121 of 1167
AI Consensus
67%
Trend
stable
Per Platform
ChatGPT
28
Perplexity
33
Gemini
36

About

Uncommon Therapeutics is a biotech company founded by Noah Auerhahn — directly inspired by his daughter's diagnosis with Rett Syndrome, a severe genetic neurological disease affecting approximately 1 in 10,000 girls — applying a polytherapy approach (combining multiple therapeutic agents targeting different disease mechanisms simultaneously) to develop treatments for serious neurological and rare diseases. After improving his daughter's quality of life through a personally developed polytherapy protocol, Auerhahn founded Uncommon Therapeutics to translate these insights into pharmaceutical products for the broader Rett Syndrome patient community.

Full profile

AI Visibility Head-to-Head

26
Overall Score
27
#1
Category Rank
#1121
68
AI Consensus
67
stable
Trend
stable
19
ChatGPT
28
26
Perplexity
33
17
Gemini
36
29
Claude
22
18
Grok
33

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.